Clinical trials: Pancreatic Cancer Non-resectable
Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with…
- Conditions
- Mesothelin-Expressing Tumors, Epithelial Ovarian Cancer, Malignant Pleural Mesothelioma, Advanced, Malignant Peritoneal Mesothelioma, Advanced
- Trial name
- NCT06756035
- Testing
- CT-95
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- Context Therapeutics Inc.
Colorectal Cancer, Esophageal Cancer
Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of two different vaccines in treating patients who have cancer of the…
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00012246
- Testing
- carcinoembryonic antigen peptide 1-6D, incomplete Freund's adjuvant, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic/Colorectal Cancer
This is a clinical research study of an investigational (FDA BB-IND 10091) treatment for patients with pancreatic cancer (all stages) and advanced colorectal cancer that no longer responds to standard therapies.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Pancreatic Adenocarcinoma Metastatic, Colorectal Cancer Metastatic
- Trial name
- Macrobead (NCT01053013)
- Testing
- RENCA macrobeads
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- The Rogosin Institute
Pancreas Cancer, Pancreatic Cancer Metastatic
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer.
- Conditions
- Pancreas Cancer, Pancreatic Cancer Metastatic, Pancreatic Cancer (Unresectable)
- Trial name
- PANACEA (NCT06549751)
- Testing
- MT-601 dose 200 million cells, MT-601 dose 400 million cells, MT-601 dose 800 million cells
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Marker Therapeutics, Inc.
Pancreatic Cancer
Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer
The purpose of this study is to determine whether the use of an FDA approved endoscopic bipolar catheter (EndoHPB) will ablate tissue in malignant tumors within the pancreatic ducts.
- Trial name
- EndoHPB (NCT02042859)
- Testing
- Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer
- Volunteers
- 40 people
- Sponsor
- Ochsner Health System
Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight.
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma
- Trial name
- NCT05642962
- Testing
- Pertzye
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Pancreatic Adenocarcinoma
Surgery for Locally Unresectable Pancreatic Cancer
Pancreatic cancer is a severe disease often diagnosed at an advanced stage, when surgery is not possible. New chemotherapy treatments can sometimes shrink the tumor and make surgery an option.
- Trial name
- ROBIN (NCT07241663)
- Testing
- Questionnaire
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Azienda Ospedaliera di Padova
Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma
FAZA PET/MRI Pancreas
This is a single arm, single centre, investigator initiated study to investigate the use of FAZA-PET in combination with MRI. FAZA is an investigational radiotracer used in PET scans.
- Conditions
- Pancreatic Adenocarcinoma Non-resectable, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer
- Trial name
- NCT04395469
- Testing
- 18F-FAZA
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Pancreatic Cancer
Gemcitabine With or Without WX-671 in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499265
- Testing
- gemcitabine hydrochloride, Serine Proteinase Inhibitor WX-671
- Where
- 39 sites in Germany, Hungary and 4 more
- Volunteers
- 95 people
- Sponsor
- Heidelberg Pharma AG
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects and best dose of TR-002 for the treatment of solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
- Trial name
- NCT07189195
- Testing
- TR-002
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of California, Davis
Pancreatic Cancer
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
The study is being conducted to evaluate the efficacy, safety and tolerability of SHR6390 in combination with nab-paclitaxel and gemcitabine in first-line treatment of subjects with advanced/metastatic pancreatic cancer.
- Trial name
- NCT05185869
- Testing
- SHR6390, Nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Ruijin Hospital
Localized Non-Resectable Adult Liver Carcinoma
Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study
This research registry studies Yttrium Y 90 resin microspheres in collecting data from patients with liver cancer not capable of being removed by surgery (unresectable) for the radiation-emitting Selective Internal…
- Trial name
- RESiN (NCT02685631)
- Testing
- Yttrium-90 Resin Microspheres
- Where
- 42 sites in United States
- Volunteers
- 1,653 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
Phase I trial to study the effectiveness of combining UCN-01 with gemcitabine in treating patients who have unresectable or metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00039403
- Testing
- 7-hydroxystaurosporine, gemcitabine hydrochloride, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma
This is an open label, single institution, dose-escalation phase 1 study designed to assess the feasibility, safety, and efficacy of oxaliplatin administered via Pancreatic Retrograde Venous Infusion (PRVI) using Pressure Enabled…
- Trial name
- PANC-001 (NCT04270929)
- Testing
- FOLFIRI, FOLFIRINOX, TriSalus Infusion System
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Carcinoma, Pancreatic Ductal
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
- Trial name
- NCT00471146
- Testing
- AG-013736, Gemcitabine
- Where
- 204 sites in United States, Argentina and 22 more
- Volunteers
- 630 people
- Sponsor
- Pfizer
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Pancreatic Neoplasms
Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer
Patients with locally advanced or metastatic pancreatic adenocarcinoma not eligible for infusional fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) (PPS 2 or hyperbilirubinemia, among other causes) will be treated with mFLOX…
- Trial name
- PanFLOX (NCT02896803)
- Testing
- mFLOX
- Where
- Brazil
- Volunteers
- 37 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Pancreatic Cancer Non-resectable, Chemotherapy Effect
Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer
In patients diagnosed with locally advanced pancreatic cancer (LAPC)/borderline resectable pancreatic cancer (BRPC) and planned chemotherapy using FOLFIRINOX, high intensity focused ultrasound (HIFU)/FOLFIRINOX combined treatment…
- Conditions
- Pancreatic Cancer Non-resectable, Chemotherapy Effect, Ultrasound Therapy
- Trial name
- NCT05262452
- Testing
- ALPIUS 900, an ultrasound-guided high intensity focused ultrasound system, FOLFIRINOX regimen
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
This phase I trial is studying the side effects and best dose of erlotinib when given together with gemcitabine and radiation therapy in treating patients with locally advanced unresectable pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT00063947
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride, radiation therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Unresectable Locally Advanced Pancreatic Carcinoma
Safety and Efficacy of NRT6008 Administered in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Carcinoma (LAPC)
This is a phase Ib, open-label study to evaluate safety and efficacy of NRT6008 in combination with standard-of-care chemotherapy in patients with unresectable Locally Advanced Pancreatic Carcinoma (LAPC).
- Trial name
- NCT07555587
- Testing
- NRT6008 Injection, Systematic chemotherapy
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- NRT MedTech Australia Pty Ltd